What Was Approved?
On August 6, 2025, the U.S. Food and Drug Administration granted accelerated approval to Modeyso (dordaviprone) for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation whose disease has progressed after prior therapy.
Modeyso is the first FDA-approved systemic therapy specifically for H3 K27M-mutant diffuse midline glioma.
How Does Modeyso Work?
Modeyso is a protease activator.
Its exact antitumor effects involve cellular stress and signaling pathways that can contribute to cancer-cell death. Treatment is intended only for tumors with the qualifying H3 K27M mutation.
How Is Modeyso Taken?
Modeyso is taken by mouth once weekly without food.
The dose is based on body size and age according to the FDA-approved prescribing information.
For patients who cannot swallow capsules, the capsule contents may be mixed with certain liquids according to the product instructions.
Why Was It Granted Accelerated Approval?
FDA granted accelerated approval based on overall response rate and duration of response from patients treated across five open-label, non-randomized clinical studies.
Continued approval may depend on confirmatory trials that verify clinical benefit. FDA currently lists Modeyso among ongoing cancer accelerated approvals.
Is Biomarker Testing Required?
Yes.
Patients should be selected for treatment based on the presence of an H3 K27M mutation in tumor tissue.
The prescribing information notes that an FDA-approved test for this mutation was not available at the time of the original approval.
What Monitoring Is Important?
The FDA label recommends monitoring electrocardiograms and electrolytes before treatment and periodically during therapy when clinically appropriate.
Because Modeyso is used in patients with a serious central nervous system cancer, treatment should be managed by an oncology team experienced with diffuse midline glioma.
Bottom Line
Modeyso (dordaviprone) is an FDA-approved once-weekly oral treatment for patients age 1 and older with H3 K27M-mutant diffuse midline glioma that has progressed after prior therapy.
The approval was granted through the accelerated approval pathway, so confirmatory studies are still required to verify the treatment’s clinical benefit.
Sources
- U.S. Food and Drug Administration (FDA) — FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma, August 6, 2025.
- U.S. Food and Drug Administration (FDA) — Drug Trials Snapshot: Modeyso.
- U.S. Food and Drug Administration (FDA) — Modeyso (dordaviprone) Prescribing Information, 2025.